Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.
Identifieur interne : 001836 ( Main/Exploration ); précédent : 001835; suivant : 001837Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.
Auteurs : Amélie Moreau [France] ; Marc Le Vée [France] ; Elodie Jouan [France] ; Claire Denizot [France] ; Yannick Parmentier [France] ; Olivier Fardel [France]Source :
- European journal of drug metabolism and pharmacokinetics [ 2107-0180 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Anticorps monoclonaux humanisés (pharmacologie), Cytochrome P-450 CYP3A (métabolisme), Femelle, Humains, Hépatocytes (), Hépatocytes (métabolisme), Interactions médicamenteuses (physiologie), Interleukine-1 bêta (métabolisme), Lignée cellulaire, Sujet âgé, Transport biologique (), Transporteurs d'anions organiques (métabolisme).
- MESH :
- métabolisme : Cytochrome P-450 CYP3A, Hépatocytes, Interleukine-1 bêta, Transporteurs d'anions organiques.
- pharmacologie : Anticorps monoclonaux humanisés.
- physiologie : Interactions médicamenteuses.
- Adulte d'âge moyen, Femelle, Humains, Hépatocytes, Lignée cellulaire, Sujet âgé, Transport biologique.
English descriptors
- KwdEn :
- Aged, Antibodies, Monoclonal, Humanized (pharmacology), Biological Transport (drug effects), Cell Line, Cytochrome P-450 CYP3A (metabolism), Drug Interactions (physiology), Female, Hepatocytes (drug effects), Hepatocytes (metabolism), Humans, Interleukin-1beta (metabolism), Middle Aged, Organic Anion Transporters (metabolism).
- MESH :
- chemical , metabolism : Cytochrome P-450 CYP3A, Interleukin-1beta, Organic Anion Transporters.
- chemical , pharmacology : Antibodies, Monoclonal, Humanized.
- drug effects : Biological Transport, Hepatocytes.
- metabolism : Hepatocytes.
- physiology : Drug Interactions.
- Aged, Cell Line, Female, Humans, Middle Aged.
- mix :
Abstract
Gevokizumab is a potent anti-interleukin (IL)-1β neutralizing monoclonal antibody (mAb), which may be used for treating inflammatory or autoimmune diseases. The present study was designed to characterize the potential effects of this mAb towards well-established IL-1β-mediated repression of hepatic drug detoxifying proteins, like cytochrome P450 (CYP) 3A4 and drug transporters.
Url:
DOI: 10.1007/s13318-017-0406-1
PubMed: 28260174
Affiliations:
- France
- Centre-Val de Loire, Languedoc-Roussillon, Occitanie (région administrative), Région Centre
- Orléans, Rennes
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C15
- to stream PubMed, to step Curation: 000C15
- to stream PubMed, to step Checkpoint: 000B74
- to stream Ncbi, to step Merge: 001496
- to stream Ncbi, to step Curation: 001496
- to stream Ncbi, to step Checkpoint: 001496
- to stream Hal, to step Corpus: 000022
- to stream Hal, to step Curation: 000022
- to stream Hal, to step Checkpoint: 000048
- to stream Main, to step Merge: 001835
- to stream Main, to step Curation: 001836
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.</title><author><name sortKey="Moreau, Amelie" sort="Moreau, Amelie" uniqKey="Moreau A" first="Amélie" last="Moreau">Amélie Moreau</name><affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Le Vee, Marc" sort="Le Vee, Marc" uniqKey="Le Vee M" first="Marc" last="Le Vée">Marc Le Vée</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Jouan, Elodie" sort="Jouan, Elodie" uniqKey="Jouan E" first="Elodie" last="Jouan">Elodie Jouan</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Denizot, Claire" sort="Denizot, Claire" uniqKey="Denizot C" first="Claire" last="Denizot">Claire Denizot</name><affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Parmentier, Yannick" sort="Parmentier, Yannick" uniqKey="Parmentier Y" first="Yannick" last="Parmentier">Yannick Parmentier</name><affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Fardel, Olivier" sort="Fardel, Olivier" uniqKey="Fardel O" first="Olivier" last="Fardel">Olivier Fardel</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes, France. olivier.fardel@univ-rennes1.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Rennes</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28260174</idno><idno type="pmid">28260174</idno><idno type="doi">10.1007/s13318-017-0406-1</idno><idno type="wicri:Area/PubMed/Corpus">000C15</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C15</idno><idno type="wicri:Area/PubMed/Curation">000C15</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C15</idno><idno type="wicri:Area/PubMed/Checkpoint">000B74</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B74</idno><idno type="wicri:Area/Ncbi/Merge">001496</idno><idno type="wicri:Area/Ncbi/Curation">001496</idno><idno type="wicri:Area/Ncbi/Checkpoint">001496</idno><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01616062</idno><idno type="url">https://hal-univ-rennes1.archives-ouvertes.fr/hal-01616062</idno><idno type="wicri:Area/Hal/Corpus">000022</idno><idno type="wicri:Area/Hal/Curation">000022</idno><idno type="wicri:Area/Hal/Checkpoint">000048</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000048</idno><idno type="wicri:doubleKey">0378-7966:2017:Moreau A:effect:of:gevokizumab</idno><idno type="wicri:Area/Main/Merge">001835</idno><idno type="wicri:Area/Main/Curation">001836</idno><idno type="wicri:Area/Main/Exploration">001836</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.</title><author><name sortKey="Moreau, Amelie" sort="Moreau, Amelie" uniqKey="Moreau A" first="Amélie" last="Moreau">Amélie Moreau</name><affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Le Vee, Marc" sort="Le Vee, Marc" uniqKey="Le Vee M" first="Marc" last="Le Vée">Marc Le Vée</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Jouan, Elodie" sort="Jouan, Elodie" uniqKey="Jouan E" first="Elodie" last="Jouan">Elodie Jouan</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Denizot, Claire" sort="Denizot, Claire" uniqKey="Denizot C" first="Claire" last="Denizot">Claire Denizot</name><affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Parmentier, Yannick" sort="Parmentier, Yannick" uniqKey="Parmentier Y" first="Yannick" last="Parmentier">Yannick Parmentier</name><affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Recherche en Pharmacocinétique, Technologie Servier, Orléans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation></author><author><name sortKey="Fardel, Olivier" sort="Fardel, Olivier" uniqKey="Fardel O" first="Olivier" last="Fardel">Olivier Fardel</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes, France. olivier.fardel@univ-rennes1.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches en Santé, Environnement et Travail (IRSET) UMR INSERM U1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 34043, Rennes</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Rennes</settlement></placeName></affiliation></author></analytic><series><title level="j">European journal of drug metabolism and pharmacokinetics</title><idno type="eISSN">2107-0180</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antibodies, Monoclonal, Humanized (pharmacology)</term><term>Biological Transport (drug effects)</term><term>Cell Line</term><term>Cytochrome P-450 CYP3A (metabolism)</term><term>Drug Interactions (physiology)</term><term>Female</term><term>Hepatocytes (drug effects)</term><term>Hepatocytes (metabolism)</term><term>Humans</term><term>Interleukin-1beta (metabolism)</term><term>Middle Aged</term><term>Organic Anion Transporters (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (pharmacologie)</term><term>Cytochrome P-450 CYP3A (métabolisme)</term><term>Femelle</term><term>Humains</term><term>Hépatocytes ()</term><term>Hépatocytes (métabolisme)</term><term>Interactions médicamenteuses (physiologie)</term><term>Interleukine-1 bêta (métabolisme)</term><term>Lignée cellulaire</term><term>Sujet âgé</term><term>Transport biologique ()</term><term>Transporteurs d'anions organiques (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytochrome P-450 CYP3A</term><term>Interleukin-1beta</term><term>Organic Anion Transporters</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Biological Transport</term><term>Hepatocytes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Hepatocytes</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytochrome P-450 CYP3A</term><term>Hépatocytes</term><term>Interleukine-1 bêta</term><term>Transporteurs d'anions organiques</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Interactions médicamenteuses</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Drug Interactions</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cell Line</term><term>Female</term><term>Humans</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Hépatocytes</term><term>Lignée cellulaire</term><term>Sujet âgé</term><term>Transport biologique</term></keywords><keywords scheme="mix" xml:lang="en"><term>Denosumab</term><term>Drug Transporter</term><term>Human Hepatocyte</term><term>Probenecid</term><term>Tocilizumab</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Gevokizumab is a potent anti-interleukin (IL)-1β neutralizing monoclonal antibody (mAb), which may be used for treating inflammatory or autoimmune diseases. The present study was designed to characterize the potential effects of this mAb towards well-established IL-1β-mediated repression of hepatic drug detoxifying proteins, like cytochrome P450 (CYP) 3A4 and drug transporters.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Centre-Val de Loire</li><li>Languedoc-Roussillon</li><li>Occitanie (région administrative)</li><li>Région Centre</li></region><settlement><li>Orléans</li><li>Rennes</li></settlement></list><tree><country name="France"><region name="Centre-Val de Loire"><name sortKey="Moreau, Amelie" sort="Moreau, Amelie" uniqKey="Moreau A" first="Amélie" last="Moreau">Amélie Moreau</name></region><name sortKey="Denizot, Claire" sort="Denizot, Claire" uniqKey="Denizot C" first="Claire" last="Denizot">Claire Denizot</name><name sortKey="Fardel, Olivier" sort="Fardel, Olivier" uniqKey="Fardel O" first="Olivier" last="Fardel">Olivier Fardel</name><name sortKey="Jouan, Elodie" sort="Jouan, Elodie" uniqKey="Jouan E" first="Elodie" last="Jouan">Elodie Jouan</name><name sortKey="Le Vee, Marc" sort="Le Vee, Marc" uniqKey="Le Vee M" first="Marc" last="Le Vée">Marc Le Vée</name><name sortKey="Parmentier, Yannick" sort="Parmentier, Yannick" uniqKey="Parmentier Y" first="Yannick" last="Parmentier">Yannick Parmentier</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001836 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001836 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28260174
|texte= Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28260174" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |